Bijal Prajapati

Parul University, India

Title: Bijal Prajapati has expertise in Formulation and Evaluation of various nanotechnology-based Pharmaceutical Preparations like Solid lipid nanoparticles, Preliposomes, Insitu hydrogel, Nanostructured lipid carriers, Microemulsion, Spanlastics, as well as dosage forms like Solid liquid compacts, Topica

---

Biography

Bijal Prajapati has expertise in Formulation and Evaluation of various nanotechnology-based Pharmaceutical Preparations like Solid lipid nanoparticles, Preliposomes, Insitu hydrogel, Nanostructured lipid carriers, Microemulsion, Spanlastics, as well as dosage forms like Solid liquid compacts, Topical formulations, Transdermal Drug delivery systems, Scaffolds. Risk Assessment studies applied to Product development. Actively working on the development of Nano formulations for CNS disorders. She has successfully developed Nano formulations for Schizophrenia and Bipolar disorders. She has skill in Risk Assessment studies for Product development, Applications of QbD approach and DoE in formulation development. Currently working for development of anticancer nanomedicines for Breast cancer. Expertise on operation and handling of HSH, HPH, Probe sonicator, Zeta sizer, E spinning technology.

Abstract

Abstract:

Recent advances in nanotechnology has promoted to the development of Nanomedicine as innovative architypes used for biomedical applications and optimized therapy. Nanomedicines with the unique features of a large surface area, structural properties, and a long circulation time in blood compared with small molecules, has been developed, with the potential to transform the diagnosis and treatment of cancer.

Objectives:

The present study mainly focuses on the development and evaluation of nanostructured lipid carriers (NLCs) for the oral route to overcome the problem of lower bioavailability of poorly soluble anticancer drug.

Scope:

Nanoformulations like NLCs can improve the efficacy of drug, which is a blend of solid lipid and liquid, which results in a partially crystallized lipid system, either through an active or passive targeting approach against cancer.

Methods:

The NLCs of poorly soluble anticancer drug was prepared by hot homogenization method using High speed homogenizer and High pressure homogenizer. The process parameters were optimized using 32 Factorial design and formulation parameters by Box-Behnken Design. Screening of lipids done based on maximum solubility of drug in lipids. Compatibility of drug and formulation components studied by FTIR. Various assessment parameters characterized for the optimized formulation and stability study conducted as per ICH guidelines for 3 months.

Results:

The optimized NLCs exhibited mean particle size of 125.35 ± 2.75 nm, Polydispersity Index of 0.349 ± 0.032, and Entrapment efficiency of 82.27±1.67 %. The TEM analysis shown the spherical size of NLCs and uniform drug distribution. An In vitro drug release study was proven by using the 0.1 N HCl pH 1.2 and Phosphate Buffer pH 6.8 with % cumulative drug release of 85.52 ± 6.41 and 88.82 ± 58.34 respectively comparable to plain drug solution.

Conclusion:

A low-dose Nanomedicine with improved bioavailability was successfully developed with predicted sustained drug release. The optimized formulation found stable with respect to Entrapment efficiency, Particle size and PDI. The results showed a prominent potential for bioavailability enhancement of anticancer drug and effective breast cancer therapy.